Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

How to optimize HCV therapy in genotype 1 patients: predictors of response.

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2013

Petta Salvatore, Craxì Antonio

Abstract excerpt

The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in addition to pegylated interferon and ribavirin (PEG-IFN/RBV) has resulted in a significant improvement in the sustained virological response (SVR) rate and potentially in life years gained compared to dual therapy (DT), when treating naïve or treatment-experienced patients with genotype 1 (G1)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferons
Share to Interleukins
Share to Liver Cirrhosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Patient Selection

Share to Pharmacogenetics

Share to Precision Medicine

Source

Identifiers

PMID: 23286842
DOI: 10.1111/liv.12053

Genes

BOC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

How to optimize HCV therapy in genotype 1 patients: predictors of response.PMID 23286842Read ↗

How to optimize HCV therapy in genotype 1 patients with cirrhosis.Semantic proximity Read ↗

How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.Semantic proximity Read ↗

Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.Semantic proximity Read ↗

Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.Semantic proximity Read ↗

[Treatment of chronic hepatitis C virus infection. A study of best predictors for response].Semantic proximity Read ↗

Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage.Semantic proximity Read ↗

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Semantic proximity Read ↗

How to optimize HCV therapy in genotype 2 patients.Semantic proximity Read ↗

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.Semantic proximity Read ↗

Optimal therapy in genotype 1 patients.Semantic proximity Read ↗

Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.Semantic proximity Read ↗

A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.